Desoize B, Robert J
GIBSA, Faculté de Pharmacie, Laboratoire de Pharmacologie, Institut Jean Godinot, Reims, France.
Eur J Cancer. 1994;30A(6):844-51. doi: 10.1016/0959-8049(94)90304-2.
The dose of anticancer drugs is currently adjusted to the patient body surface area, although patients have different abilities to clear anticancer drugs. The dose adjustment to physiological functions permits major toxic accidents to be avoided. The adjustment to tumour drug content is considered, but for ethical or technical reasons, it cannot be used routinely The best criterion for the dose adjustment seems to be drug plasma concentration. The relationship between plasma concentration and efficacy may not be excellent, since it depends on the presence of resistant cells and on the blood flow through the tumour. A relationship between plasma concentration and/or the area under the curve (AUC) with toxicity has been reported with all major anticancer drugs. Different methods of dose adjustment to the drug plasma concentration are reported. In conclusion, dose adjustment to the drug plasma concentration or to the AUC can improve the chemotherapy efficacy, while reducing toxicity.
目前，抗癌药物的剂量是根据患者的体表面积进行调整的，尽管患者清除抗癌药物的能力各不相同。根据生理功能调整剂量可避免重大毒性事故的发生。虽然考虑过根据肿瘤药物含量进行调整，但出于伦理或技术原因，无法常规使用。剂量调整的最佳标准似乎是药物血浆浓度。血浆浓度与疗效之间的关系可能并不理想，因为这取决于耐药细胞的存在以及肿瘤的血流情况。所有主要抗癌药物都有关于血浆浓度和/或曲线下面积（AUC）与毒性之间关系的报道。也有不同的根据药物血浆浓度进行剂量调整的方法。总之，根据药物血浆浓度或AUC进行剂量调整可以提高化疗疗效，同时降低毒性。
